Filtered By:
Drug: Simvastatin

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 124 results found since Jan 2013.

Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis study
Conclusion: Rate of AF is moderate in asymptomatic AS. Longstanding but not episodic AF was, independently predictive of increased risk of heart failure and non-hemorrhagic stroke. New-onset AF was associated with cardiac decompensation.
Source: International Journal of Cardiology - October 13, 2011 Category: Cardiology Authors: Anders M. Greve, Eva Gerdts, Kurt Boman, Christa Gohlke-Baerwolf, Anne B. Rossebø, Christoph A. Nienaber, Simon Ray, Kenneth Egstrup, Terje R. Pedersen, Lars Køber, Ronnie Willenheimer, Kristian Wachtell Tags: Original Articles Source Type: research

Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: The simvastatin and ezetimibe in aortic stenosis study
Abstract: Background: Left atrial (LA) size and function change with chronically increased left ventricular (LV) filling pressures. It remains unclear whether these variations in LA parameters can predict new-onset atrial fibrillation (AF) in asymptomatic patients with aortic stenosis (AS).Methods: Data were obtained in asymptomatic patients with mild-to-moderate AS (2.5≤ transaortic Doppler velocity ≤4.0m/s), preserved LV ejection fraction (EF), no previous AF, and were enrolled in the Simvastatin and Ezetimibe in Aortic Stenosis study. Peak-aortic velocity, LAmax volume & LAmin volume were measured by echocardiograph...
Source: International Journal of Cardiology - February 18, 2013 Category: Cardiology Authors: Casper N. Bang, Morten Dalsgaard, Anders M. Greve, Lars Køber, Christa Gohlke-Baerwolf, Simon Ray, Anne B. Rossebø, Kenneth Egstrup, Kristian Wachtell Tags: Original Articles Source Type: research

Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial.
CONCLUSIONSIn the ACCORD BP trial, compared with combined standard treatment, intensive BP or intensive glycemia treatment alone improved major CVD outcomes, without additional benefit from combining the two. In the ACCORD lipid trial, neither intensive lipid nor glycemia treatment produced an overall benefit, but intensive glycemia treatment increased mortality. PMID: 24595629 [PubMed - as supplied by publisher]
Source: Diabetes Care - March 4, 2014 Category: Endocrinology Authors: Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH, Lipkin EW, Venkat Narayan KM, Riddle MC, Sood A, Goff DC Tags: Diabetes Care Source Type: research

Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL)
Clinical trials have not provided evidence for a role of statin therapy in reducing aortic valve stenosis (AVS) severity in patients with documented AVS. However, whether statin therapy could prevent the onset of AVS is unknown. Our objectives were (1) to compare the incidence rates of AVS among patients treated with high-dose versus usual-dose statin or placebo and (2) to identify clinical risk factors associated with the development of AVS. We conducted post hoc analyses in 23,508 participants from 3 large-scale multicenter atorvastatin randomized blinded clinical trials: Treating to New Targets, the Incremental Decrease...
Source: The American Journal of Cardiology - February 3, 2014 Category: Cardiology Authors: Benoit J. Arsenault, S. Matthijs Boekholdt, Samia Mora, David A. DeMicco, Weihang Bao, Jean-Claude Tardif, Pierre Amarenco, Terje Pedersen, Philip Barter, David D. Waters Tags: Valvular Heart Disease Source Type: research

Assessing Patient Decision-Making Capacity: It’s About the Thought Process
Fred Jones is a 64-year-old man who presents to the emergency department with visual changes and left-sided facial numbness that started 2 hours earlier, after an argument with his wife. He states, “I want to make sure I’m not having a stroke.” His medical history is significant for hypertension. His medications include lisinopril, hydrochlorothiazide, and simvastatin. He is being evaluated for a cerebral vascular accident (CVA) with an onset of symptoms of less than 4 hours. Nursing assessment finds a National Institutes of Health Stroke Scale score of 1, with the loss of left upper quadrant peripheral visual fields.
Source: Journal of Emergency Nursing: JEN - January 9, 2015 Category: Nursing Authors: Melanie A. Mitchell Tags: Clinical Source Type: research

Cerebrovascular neurosurgery 2014
Publication date: Available online 14 February 2015 Source:Journal of Clinical Neuroscience Author(s): Mohamed Salem , Bradley A. Gross , Rose Du , Ajith J. Thomas Continued advances in our understanding of the management of cerebrovascular disease were made in 2014. A randomized trial for management of unruptured brain arteriovenous malformation (ARUBA) (Mohr et al. Lancet 2014;383:614–21.) and the Scottish intracranial vascular malformation study (Al-Shahi Salman et al. JAMA 2014;311:1661–9) were published and contrasted with reports based on extensive surgical experience. We highlight the results from the simvasta...
Source: Journal of Clinical Neuroscience - February 16, 2015 Category: Neuroscience Source Type: research

Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications.
CONCLUSION: Early introduction of dual antiplatelet therapy was associated with a significant reduction in recurrent neurological events and spontaneous embolization prior to CEA, without incurring a significant increase in major peri-operative bleeding complications. PMID: 26283034 [PubMed - as supplied by publisher]
Source: PubMed: Eur J Vasc Endovasc ... - August 14, 2015 Category: Surgery Authors: Batchelder A, Hunter J, Cairns V, Sandford R, Munshi A, Naylor AR Tags: Eur J Vasc Endovasc Surg Source Type: research

The Jekyll and Hyde of Statins
By Drs. David Niesel and Norbert Herzog, Medical Discovery News Cholesterol-lowering drugs called statins are the most prescribed drug ever. About 30 percent of Americans are currently taking statins such as Crestor, Lipitor, Mevacor and Zocor. Overall, statins can be good thing, but as with all drugs, there are some negative effects. Statins lower cholesterol by inhibiting a protein called HMG-CoA reductase. Since high cholesterol levels are linked to heart disease, statins can reduce the risks of heart attack and stroke, two of the leading causes of death in the United States. Recent reports from the American Heart Assoc...
Source: Science - The Huffington Post - February 3, 2016 Category: Science Source Type: news

Severe Symptoms, but a Truly Treatable Disease
​BY NOURA MAHDI; DARRON LEWIS; JEREMY OSBORNE; & AHMED RAZIUDDIN, MDA 73-year-old man was brought to the emergency department from his nursing home for rectal bleeding and anemia. The patient mentioned he had had episodes of bright red rectal bleeding and constipation for a few months. A colonoscopy had been done prior to the visit, which revealed a large intestine tumor and biopsy confirming adenocarcinoma. He was awaiting an appointment with his surgeon.The patient reported bloody rectal leakage, and a CBC done at the nursing home showed a hemoglobin level of 7.2. He also complained of dyspnea but denied any other ...
Source: The Case Files - March 20, 2018 Category: Emergency Medicine Tags: Blog Posts Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
In this interview with Dr. Lee Hooper we find out more about this new Cochrane review -Omega-3 fatty acids for the primary and secondary prevention of cardiovascular diseaseTell us about this Cochrane ReviewThere is a great deal of public belief in the cardiovascular benefits of omega-3 fats.   Intakes of long-chain omega-3 fats in the US are higher from dietary supplements than foods.  But public health advice differs across countries. The National Institute for Health and Clinical Excellence in the UK encourages people to eat oily fish intake (the major source of long-chain omega-3 f ats) but discourages supplementatio...
Source: Cochrane News and Events - February 5, 2020 Category: Information Technology Authors: Katie Abbotts Source Type: news

Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy Effect of Baseline Risk Factors for Diabetes
ConclusionsCompared with lower-dose statin therapy, atorvastatin 80 mg/day did not increase the incidence of NOD in patients with 0 to 1 NOD risk factors but did, by 24%, among patients with 2 to 4 NOD risk factors. The number of CV events was significantly reduced with atorvastatin 80 mg in both NOD risk groups.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 7, 2013 Category: Cardiology Source Type: research

The Current State of Niacin in Cardiovascular Disease Prevention A Systematic Review and Meta-Regression
ConclusionsThe consensus perspective derived from available clinical data supports that niacin reduces CVD events and, further, that this may occur through a mechanism not reflected by changes in high-density lipoprotein cholesterol concentration.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 21, 2013 Category: Cardiology Source Type: research

The Current State of Niacin in Cardiovascular Disease Prevention: A Systematic Review and Meta-Regression
Conclusions: The consensus perspective derived from available clinical data supports that niacin reduces CVD events and, further, that this may occur through a mechanism not reflected by changes in high-density lipoprotein cholesterol concentration.
Source: Journal of the American College of Cardiology - December 26, 2012 Category: Cardiology Authors: Paul M. Lavigne, Richard H. Karas Tags: Cardiometabolic Risk Source Type: research

Relationship of Lipoproteins to Cardiovascular Events The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial.BackgroundDuring a 3-year follow-up in 3,414 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, combined niacin + low-density lipoprotein cholesterol (LDL-C)–lowering therapy did not reduce CV events compared with LDL-C–lowering therapy alone.MethodsSubjects taking simvastatin and/or ez...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - October 14, 2013 Category: Cardiology Source Type: research